Home » Newsletters » BioWorld Science

BioWorld Science

June 28, 2011

View Archived Issues

Novel dual specificity protein kinase TTK inhibitors patented

New phase III data reported on azilsartan medoxomil potassium/chlorthalidone in hypertension

New insulin-like growth factor I receptor inhibitors synthesized

New nicotinic acetylcholine alpha7 receptor modulators claimed

Clovis Oncology expands study to identify patient stratification parameters for CP-4126 trial LEAP

Phase Ib/II data suggest PCI-32765 is safe in lymphocytic leukemia/small lymphocytic lymphoma

First-in-human trial assesses azurin-derived P28 peptide in metastatic solid cancers

First-in-human data disclosed on ONX-0912 in recurrent/refractory solid tumors

First-in-human study reveals activity of RAF-265 in melanoma

Blocking Smad1 phosphorylation may reduce diabetic nephropathy

Japan Tobacco presents novel tyrosine-protein kinase ITK/TSK inhibitors

EMA continues review of pioglitazone-based medicines

Sanofi to launch orally disintegrating Allegra tablets in Japan

Arch Cancer Therapeutics prepares new brain tumor-targeting peptides

CHMP issues negative opinion on Glybera MAA

Genmab shelves development activity for zalutumumab

Evotec and Ono continue ion channel drug discovery collaboration

Akebia begins new phase IIa AKB-6548 trial in patients with chronic kidney disease and anemia

CHMP issues negative opinion on Bronchitol for cystic fibrosis

FDA lifts clinical hold on phase II Cavatak trial in melanoma

Boehringer Ingelheim begins development program for Ablynx nanobody

FDA committee recommends approval of Firazyr for hereditary angioedema attacks

FDA grants orphan drug status to Revimmune in systemic sclerosis and autoimmune hemolytic anemia

FDA accepts Prochieve progesterone gel NDA for filing

FDA grants fast track status to SBC-102 in lysosomal acid lipase deficiency

Arno Therapeutics reports interim phase II data on AR-67 in glioblastoma multiforme

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...